Presentation on theme: "AOA/OMED 10/1/13 Eric P. Baron, DO Cleveland Clinic Neurological Institute Center for Regional Neurology."— Presentation transcript:
AOA/OMED 10/1/13 Eric P. Baron, DO Cleveland Clinic Neurological Institute Center for Regional Neurology
In 2008, fell from 3 rd to 4 th leading cause of death in the US after heart disease, cancer, and chronic lower respiratory diseases >795,000 people in US have a stroke each year. -About 610,000 of these are first or new strokes. -1 in 4 are recurrent strokes. >137,000 deaths each year (1 in every 18 deaths) http://www.strokeassociation.org/STROKEORG/AboutStroke/Impact-of-Stroke-Stroke- statistics_UCM_310728_Article.jsp
About 40% of stroke deaths occur in males, and 60% in females. An American has a stroke every 40 seconds, and every 4 minutes someone dies of stroke. Stroke costs the US >$38.6 billion per year http://www.strokeassociation.org/STROKEORG/AboutStroke/Impact-of-Stroke-Stroke- statistics_UCM_310728_Article.jsp
Ischemic Stroke (87%) A thrombus or embolus blocks blood flow to part of the brain. Hemorrhagic Stroke (13%) Blood spills out from break in blood vessel in brain
Each hour: -120 million neurons, 830 billion synapses, and 714 km (447 miles) of myelinated fibers are lost. -Compared with normal rate of neuron loss in brain aging, the ischemic brain ages 3.6 years each hour without treatment. Each minute: -1.9 million neurons, 14 billion synapses, and 12 km (7.5 miles) of myelinated fibers are destroyed. Each second: -30,000 neurons
Classical definition (1960s): Sudden, neurological deficit, usually focal, lasting < 24 hours. NIH Consensus Statement. Stroke 1975;6:564-616. Newer definition (2002): Sudden neurological deficit lasting less than 1 hour and not associated with new lesion on neuroimaging. (e.g. DWI on MRI) Albers GW et al. N Eng J Med 2002;347(21):1713-1716. New AHA endorsed definition (2009): A transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. Easton JD et al. Stroke 2009;40:2276-2293.
Reversible neurologic deficits typically <30 minutes and usually resolve within 1 hour, although may last up to 24 hours. Often called a “mini-stroke” Due to a temporary disruption of the blood supply to the brain WARNING SIGN FOR STROKE
Risk of stroke after TIA - 1/3 have continued TIAs - 1/3 have no further symptoms - 1/3 stroke within 5 years (usually 1st month) - 50% have stroke in next 2 days - 10% have stroke in next 3 months - 15% have stroke in 1 year - 25% have stroke in 5 years
40-60% of TIA pts have evidence of ischemic injury on DWI (Diffusion Weighted Imaging) Factors predicting positive DWI: Symptoms lasting > 60 minutes Focal weakness Speech impairment Kidwell C et al. Stroke 1999; 6:1174-1180. Couttts SB et al. Annals of Neurology 2005;57:848-854
Causes a 2-fold increase in risk of ischemic stroke and up to a 4-fold increase in risk of hemorrhagic stroke. Linked to the buildup of atherosclerosis. Nicotine raises BP; CO from smoking reduces the amount of oxygen blood can carry to the brain; and cigarette smoke makes blood thicker and more likely to clot. Promotes aneurysm formation. Stopping smoking causes a 50% risk reduction for stroke within 1 year. Stopping smoking causes stroke risk to approach that of nonsmokers after 5 years.
Having diabetes is the equivalent of aging 15 years. Causes destructive changes in the blood vessels throughout the body, including the brain. If blood glucose levels are high at the time of a stroke, then brain damage is usually more severe and extensive than when blood glucose is well- controlled. HTN is common among diabetics and accounts for much of the increased stroke risk.
In general, increases stroke risk by 5-fold. Responsible for 1 in 4 strokes after age 80, and is associated with higher mortality and disability. CHADS2 Score is helpful in deciding on anticoagulation: -Low risk (0): Aspirin 100-300 mg daily -Moderate risk (1): Warfarin or Aspirin -High risk (2-6): Warfarin (INR 2-3)
Warfarin (Class I; Level of Evidence A) Dabigatran 150 mg bid (Class I; Level of Evidence B) -CrCl >30 mL/min Apixaban 5 mg bid (Class I; Level of Evidence B) -No more than 1 of the following characteristics: Age >80 years, weight 1.5 mg/dL Rivaroxaban 20 mg/d (Class IIa; Level of Evidence B) -CrCl >50
Recent TIA or ischemic stroke w/in 6 months and ipsilateral severe (70%-99%) carotid stenosis: -CEA recommended if perioperative morbidity and mortality risk estimated at <6% (Class I; Level of Evidence A). Recent TIA or ischemic stroke and ipsilateral moderate (50%-69%) carotid stenosis: -CEA recommended depending on patient-specific factors such as age, sex, and comorbidities if perioperative morbidity and mortality risk estimated at <6% (Class I; Level of Evidence B).
Stenosis <50%: -No indication for carotid revascularization by either CEA or CAS (Class III; Level of Evidence A). When CEA is indicated for patients with TIA or stroke, surgery w/in 2 weeks is reasonable rather than delaying surgery if no contraindications to early revascularization (Class IIa; Level of Evidence B).
CAS indicated as alternative to CEA for symptomatic patients at average to low risk of complications associated with endovascular intervention when ICA stenosis >70% by noninvasive imaging or >50% by catheter angiography (Class I; Level of Evidence B).
Among patients with symptomatic severe stenosis (>70%) in whom the stenosis is difficult to access surgically, medical conditions are present that greatly increase the risk for surgery, or when other specific circumstances exist, such as radiation-induced stenosis or restenosis after CEA, CAS may be considered (Class IIb; Level of Evidence B). CAS in the above setting is reasonable when performed by operators with established periprocedural morbidity and mortality rates of 4-6%, similar to those observed in trials of CEA and CAS (Class IIa; Level of Evidence B).
For patients with symptomatic extracranial carotid occlusion, EC/IC bypass surgery is not routinely recommended (Class III; Level of Evidence A). Optimal medical therapy, which should include antiplatelet therapy, statin therapy, and risk factor modification, is recommended for all patients with carotid artery stenosis and a TIA or stroke as outlined elsewhere in this guideline (Class I; Level of Evidence B).
Optimal medical therapy, which should include antiplatelet therapy, statin therapy, and risk factor modification, is recommended for all patients with vertebral artery stenosis and a TIA or stroke as outlined elsewhere in this guideline (Class I; Level of Evidence B). Endovascular and surgical treatment of patients with extracranial vertebral stenosis may be considered when patients are having symptoms despite optimal medical treatment (including antithrombotics, statins, and relevant risk factor control) (Class IIb; Level of Evidence C)
For patients with a stroke or TIA due to 50%-99% stenosis of a major intracranial artery, aspirin is recommended in preference to warfarin (Class I; Level of Evidence B). - Patients in the WASID trial were treated with aspirin 1300 mg/d, but the optimal dose of aspirin in this population has not been determined. - On the basis of data on general safety and efficacy, aspirin doses of 50 mg/d to 325 mg/d are recommended (Class I; Level of Evidence B).
For patients with stroke or TIA due to 50% to 99% stenosis of a major intracranial artery, long-term maintenance of BP <140/90 mm Hg and total cholesterol level <200 mg/dL may be reasonable (Class IIb; Level of Evidence B).
For patients with stroke or TIA due to 50%-99% stenosis of a major intracranial artery, the usefulness of angioplasty and/or stent placement is unknown and is considered investigational (Class IIb; Level of Evidence C). For patients with stroke or TIA due to 50%-99% stenosis of a major intracranial artery, EC/IC bypass surgery is not recommended (Class III; Level of Evidence B).
Age Sex Low birth weight Race/ethnicity Genetic predisposition
Stroke occurs in all age groups, including childhood or adolescence. Studies show the risk of stroke doubles for each decade between the ages of 55 and 85.
Men have a higher risk for stroke, but more women die from stroke. Men generally do not live as long as women, so men are usually younger when they have their strokes and therefore have a higher rate of survival.
In African Americans stroke is more common and more deadly across all age groups. Studies show that the age-adjusted incidence of stroke is about twice as high in African Americans and Hispanic Americans as in Caucasians. An important risk factor for African-Americans is sickle cell disease, which can cause a narrowing of arteries and disrupt blood flow.
Members of a family might have a genetic tendency for stroke risk factors, such as an inherited predisposition for HTN, HLP, DM, etc. The influence of a common lifestyle among family members also could contribute to familial stroke.
Stroke risk factor modifications (including antiplatelet therapy (or anticoagulation if indicated), HLP, HTN, DM, Smoking, etc.): -Primary (prior to an event) -Secondary (following an event) Improving patient education for rapid symptom evaluation due to short intervention treatment windows (tPA)
Confusion, trouble speaking or understanding Trouble seeing in one or both eyes Trouble walking, dizziness, loss of balance or coordination Severe headache with no known cause Numbness or weakness of face, arm or leg, especially on one side
Cardiac monitoring BP - <180/105 following tPA and lower BP by 15% per day - <220/120 if no tPA and lower BP by 15% per day Airway support as needed and O2 sats >94% Temp < 38°C (100.4°F) Treat hypoglycemia (<60 mg/dL) and hyperglycemia (optimal range 140-180 mg/dL) Treat hypovolemia with IV NS Head of bed 15-30°
Catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown. 0.9 mg/kg IV (max dose 90 mg) -10% given as a bolus over 1 minute -Remaining 90% continuous infusion over 60 minutes No antiplatelet/anticoagulants x 24 hours post-tPA
NINDS trial in 1995 (National Institute of Neurological Disorders and Stroke) rtPA Stroke Study Group: -In 1996 US FDA approved IV tPA for acute ischemic stroke within 3 hrs of symptom onset (Class I; Level of Evidence A)
ECASS-3 trial in 2008 (European Cooperative Acute Stroke Study) showed an extended window from 3-4.5 hours of symptom onset. -European Medicines Agency expanded approval of IV tPA to the 3-4.5 hour window. -US FDA has not officially approved this. -However, AHA/ASA has labeled this Class I; Level of Evidence B in revised stroke guidelines published 1/31/13, and is considered standard of care.
Modified Rankin Scale of 0-1 at 3 months: NINDS: 39% (rtPA) vs. 26% (control) OR 1.7 (1.1-2.6) P = 0.019 ECASS-3: 52% (rtPA) vs. 45% (control) OR 1.34 (1.02-1.74) P = 0.04
Symptomatic ICH (NINDS definition): NINDS: 6.4% vs. 0.6% (placebo) P < 0.001 ECASS-3: 7.9% vs. 3.5% (placebo) P = 0.006
Death at 3 months: NINDS: 17% vs. 24% (placebo) P = 0.3 ECASS-3: 32% vs. 34% (placebo) P = 0.68
30% greater chance of good neurologic outcome at 3 months with IV tPA compared to without NNT to obtain significant benefit in 1 patient within 3 hour window: 8 NNT to obtain significant benefit in 1 patient within 3-4.5 hour window: 23 40% get better with tPA, 28% get better without tPA, (12% absolute benefit) Significant increase in risk of ICH: 6.4% (<3 hours) vs. 7.9% (3-4.5 hours)
Diagnosis of ischemic stroke causing measurable neurological deficit. Onset of symptoms <3 hours before beginning treatment (see below for 3-4.5 hours after onset). Age ≥ 18 years old
Significant head trauma or stroke in previous 3 mths. Intracranial neoplasm, aneurysm, or AVM. Symptoms of stroke should not be suggestive of subarachnoid hemorrhage. Arterial puncture at a noncompressible site in previous 7 days. History of previous intracranial hemorrhage. Recent intracranial or intraspinal surgery.
BP elevated (>185/110 mm Hg). Evidence of active internal bleeding or acute trauma (fracture) on exam. Anticoagulant use with INR >1.7 or PT >15. Taking a direct thrombin inhibitor or factor Xa within 48 hours or with elevated aPTT, INR, ECT (ecarin clotting time), TT (thrombin time), or appropriate factor Xa assay.
If received heparin in previous 48 hours, aPTT must be in normal range. Platelet count <100,000 mm3. Blood glucose concentration <50 mg/dL (2.7 mmol/L) (serum glucose is only lab test that MUST be obtained before starting tPA). CT shows multilobar infarction (hypodensity >1/3 cerebral hemisphere). tPA may be given if other early ischemic changes are seen on CT.
GI or GU hemorrhage in previous 21 days. Major surgery or major trauma in previous 14 days. Seizure at onset with postictal residual neurological impairments. Myocardial infarction in the previous 3 months. Pregnancy. Minor or rapidly improving neurological symptoms.
Same as those for earlier time periods, with any 1 of the following 4 additional exclusion criteria: 1. Age > 80 years old. 2. Any oral anticoagulant use, regardless of INR. 3. Severe stroke (NIHSS score >25). 4. Those with both history of stroke and diabetes.
Intraarterial (IA) tPA within 6 hours (Class I; Level of Evidence B) - tPA does not have FDA approval for IA use Mechanical Thrombectomy: - Within 8 hours in anterior circulation - Less defined in posterior circulation, possibly up to 24-36 hours in some cases - Stent retrievers generally preferred to coil retrievers (Class I; Level of Evidence A)
TIA should be treated as impending stroke The period of greatest risk for stroke is within 48 hours of a TIA Simple clinical features can predict those patients with TIA at greatest stroke risk IV tPA is indicated for acute ischemic stroke within 3 hours, and now up to 4.5 hours in select patients. IA tPA is indicated for acute ischemic stroke within 6 hours. Mechanical thrombectomy is indicated for acute ischemic stroke within 8 hours.